Patients with liver metastases from squamous cell head and neck cancer (SCHNC) are usually treated with chemotherapy and are not evaluated for eventual liver-directed treatment. However, the potential benefits from liver surgery for the patients with hepatic-only metastases from SCHNC generally remain undefined. We report a patient with late liver-only metastases from squamous cell glottic cancer treated with resection of the liver metastases followed by adjuvant platinum-based chemotherapy plus cetuximab. The patient died 25 months after resection of the hepatic metastases from widespread hepatic and pulmonary recurrence. The literature data as well as this case demonstrates the capability of liver surgery to prolong survival in patients with hepatic metastases from SCHNC.
 Forastiere A.A., Metch B., Schuller D.E., Ensley J.F., Hutchins L.F., Triozzi P., et al., Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol, 1992, 10, 1245–1251
 Clavel M., Vermorken J.B., Cognetti F., Cappelaere P., de Mulder P.H., Schornagel J.H., et al., Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol, 1994, 5, 521–526
Financed by the National Centre for Research and Development under grant No. SP/I/1/77065/10 by the strategic scientific research and experimental development program:
SYNAT - “Interdisciplinary System for Interactive Scientific and Scientific-Technical Information”.